NDAORALTABLETPriority Review
Approved
Nov 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
REVIA (naltrexone hydrochloride) by Teva is clinical pharmacology pharmacodynamic actions naltrexone is a pure opioid antagonist. First approved in 1984.
Drug data last refreshed 2d ago
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamic Actions Naltrexone is a pure opioid antagonist. It markedly attenuates or completely blocks, reversibly, the subjective effects of intravenously administered opioids. When coadministered with morphine, on a chronic basis, naltrexone blocks the physical…
Worked on REVIA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.